Table 1.

Age group-specific prevalence of HPV16/18 versus other HPV genotypes in cervical cancers diagnosed in Western countries (Europe, North America, and Australia; ref. 1; A), in New Mexico (12; B), and combining data from the 2 studies (C).

A. Sanjose and colleagues, 2010 (1)
HPV StatusAll ages<2525–2930–3435–3940–4445–4950–5455–5960–6465–6970–7475–79≥80Ptrend
HPV16/18N1294133191144173165152153119110683936<0.001
%Row100%1.0%2.4%7.0%11.1%13.4%12.7%11.7%11.8%9.2%8.5%5.3%3.0%2.8%
%Column74.8%100%73.7%83.3%82.3%80.1%72.3%73.4%81.0%72.4%72.5%60.1%61.1%63.2%
Other HPV GenotypesN4350111831436355364641452521
%Row100.0%0.0%2.5%4.2%7.1%9.9%14.5%12.6%8.3%10.5%9.5%10.4%5.7%4.8%
%Column25.2%0.0%26.3%16.7%17.7%19.9%27.7%26.6%19.0%27.6%27.5%39.9%38.9%36.8%
TotalN172913421091752162282071891651511136457
B. Wheeler and colleagues, 2009 (12)
HPV StatusAll ages<2525–2930–3435–3940–4445–4950–5455–5960–6465–6970–7475–79≥80Ptrend
HPV16/18N5359447080645942385120231817<0.001
%Row100%1.7%8.2%13.1%15.0%12.0%11.0%7.9%7.1%9.5%3.7%4.3%3.4%3.2%
%Column71.9%60.0%75.9%78.7%75.5%80.0%78.7%79.2%64.4%77.3%44.4%59.0%62.1%56.7%
Other HPV GenotypesN2096141926161611211525161113
%Row100.0%2.9%6.7%9.1%12.4%7.7%7.7%5.3%10.0%7.2%12.0%7.7%5.3%6.2%
%Column28.1%40.0%24.1%21.3%24.5%20.0%21.3%20.8%35.6%22.7%55.6%41.0%37.9%43.3%
TotalN744155889106807553596645392930
p =0.0180.820.460.171.00.640.480.010.51<0.0011.01.01.0
C. Combined
HPV StatusAll ages<2525–2930–3435–3940–4445–4950–5455–5960–6465–6970–7475–79≥80Ptrend
HPV16/18N18292275161224237224194191170130915753<0.001
%Row100%1.2%4.1%8.8%12.2%13.0%12.2%10.6%10.4%9.3%7.1%5.0%3.1%2.9%
%Column74.0%78.6%74.9%81.2%79.7%80.1%73.9%74.6%77.1%73.8%66.1%59.8%61.4%60.9%
Other HPV GenotypesN6446253757597966576166613634
%Row100.0%0.9%3.9%5.8%8.9%9.1%12.3%10.2%8.8%9.4%10.3%9.5%5.6%5.3%
%Column26.0%21.4%25.1%18.8%20.3%19.9%26.1%25.4%22.9%26.2%33.9%40.2%38.6%39.1%
TotalN2473281001982812963032602482311961529387

NOTE: Ptrend, a nonparametric test of trend of the fraction of HPV16/18 with increasing age; P, Fisher exact test for age-group differences in the fraction of HPV16/18 between the 2 studies. Bold type indicates statistical significance (P < 0.05).